Chemistry:Avenciguat
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | BI 685509 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C34H38N4O5 |
| Molar mass | 582.701 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Avenciguat (development name BI 685509) is a soluble guanylate cyclase activator developed by Boehringer Ingelheim for kidney disease,[1][2] and cirrhosis.[3][4][5]
References
- ↑ Cherney, David Z. I.; de Zeeuw, Dick; Heerspink, Hiddo J. L.; Cardona, Jose; Desch, Marc; Wenz, Arne; Schulze, Friedrich; Nangaku, Masaomi (August 2023). "Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial". Diabetes, Obesity and Metabolism 25 (8): 2218–2226. doi:10.1111/dom.15099. PMID 37232058.
- ↑ Reinhart, Glenn A.; Harrison, Paul C.; Lincoln, Kathleen; Chen, Hongxing; Sun, Peng; Hill, Jon; Qian, Hu Sheng; McHugh, Mark C. et al. (March 2023). "The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease". Journal of Pharmacology and Experimental Therapeutics 384 (3): 382–392. doi:10.1124/jpet.122.001423. PMID 36507845.
- ↑ Lawitz, Eric J.; Reiberger, Thomas; Schattenberg, Jörn M.; Schoelch, Corinna; Coxson, Harvey O.; Wong, Diane; Ertle, Judith (November 2023). "Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study". Hepatology Communications 7 (11). doi:10.1097/HC9.0000000000000276. PMID 37889522.
- ↑ Jones, Amanda K.; Chen, Hongxing; Ng, Khing Jow; Villalona, Jorge; McHugh, Mark; Zeveleva, Svetlana; Wilks, James; Brilisauer, Klaus et al. (July 2023). "Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model". Journal of Pharmacology and Experimental Therapeutics 386 (1): 70–79. doi:10.1124/jpet.122.001532. PMID 37230799.
- ↑ Reiberger, Thomas; Berzigotti, Annalisa; Trebicka, Jonel; Ertle, Judith; Gashaw, Isabella; Swallow, Ros; Tomisser, Andrea (24 April 2023). "The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis". Trials 24 (1): 293. doi:10.1186/s13063-023-07291-3. PMID 37095557.
 |  |
